Share on StockTwits

Haemonetics (NYSE:HAE) Director Ronald G. Gelbman unloaded 9,184 shares of the stock in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $34.00, for a total value of $312,256.00. Following the completion of the transaction, the director now directly owns 39,173 shares of the company’s stock, valued at approximately $1,331,882. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Haemonetics (NYSE:HAE) traded up 0.74% during mid-day trading on Friday, hitting $34.26. 106,103 shares of the company’s stock traded hands. Haemonetics has a 52-week low of $29.86 and a 52-week high of $45.90. The stock’s 50-day moving average is $33.21 and its 200-day moving average is $37.1. The company has a market cap of $1.783 billion and a price-to-earnings ratio of 50.76.

Haemonetics (NYSE:HAE) last announced its earnings results on Monday, April 28th. The company reported $0.46 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.58 by $0.12. The company had revenue of $241.00 million for the quarter, compared to the consensus estimate of $244.87 million. During the same quarter in the previous year, the company posted $0.48 earnings per share. The company’s revenue for the quarter was down 3.5% on a year-over-year basis. Analysts expect that Haemonetics will post $1.89 EPS for the current fiscal year.

A number of analysts have recently weighed in on HAE shares. Analysts at Jefferies Group reiterated a “buy” rating on shares of Haemonetics in a research note on Wednesday, May 21st. They now have a $38.00 price target on the stock, up previously from $36.00. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Haemonetics in a research note on Friday, March 28th. They now have a $34.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $38.00.

Haemonetics Corporation is a healthcare company engaged in providing blood management solutions to its customers.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.